3rd Quarter - Report — BUCHANAN INGERSOLL & ROONEY PC for ALLAY THERAPEUTICS (2022)

Firm

BUCHANAN INGERSOLL & ROONEY PC

Client

ALLAY THERAPEUTICS

Income

$20,000

Expenses

—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA).

Lobbyist	Covered position, as disclosed
TIMOTHY COSTA	—
ALICE HARPER NETTLES	—
MICHAEL P STRAZZELLA	—

Contacted: Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Health Issues HCR

Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA).

Lobbyist	Covered position, as disclosed
TIMOTHY COSTA	—
ALICE HARPER NETTLES	—
MICHAEL P STRAZZELLA	—

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA).

Lobbyist	Covered position, as disclosed
TIMOTHY COSTA	—
ALICE HARPER NETTLES	—
MICHAEL P STRAZZELLA	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Pharmacy PHA

Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA).

Lobbyist	Covered position, as disclosed
TIMOTHY COSTA	—
ALICE HARPER NETTLES	—
MICHAEL P STRAZZELLA	—

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.